Double-blind clinical trial of 5-hydroxytryptophan in a case of Lesch-Nyhan syndrome.

Abstract

5-Hydroxytryptophan (5-HTP) treatment of a single case of Lesch-Nyhan syndrome showing compulsive self-mutilation, athetoid movements, and characteristic clinical biochemical picture was studied on a double-blind basis. 5-HTP or placebo was administered for seven fortnightly treatment blocks. 5-HTP produced a significant reduction of athetoid movement and a sedative effect but did not improve the patient's mood or reduce self-mutilation.

• Authors: C D Frith, E C Johnston, M H Joseph, R J Powell, R W Watts
• Journal: Journal of neurology, neurosurgery, and psychiatry (J Neurol Neurosurg Psychiatry) Vol. 39 Issue 7 Pg. 656-62 (Jul 1976) ISSN: 0022-3050 [Print] England
• PMID: 792398 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• 5-Hydroxytryptophan

Topics

• 5-Hydroxytryptophan (blood, therapeutic use)
• Child
• Clinical Trials as Topic
• Drug Evaluation
• Emotions (drug effects)
• Humans
• Lesch-Nyhan Syndrome (drug therapy)
• Male
• Motor Activity (drug effects)
• Self Mutilation (drug therapy)